Orally Delivered Baclofen to Control Spastic Hypertonia in Acquired Brain Injury

Journal of Head Trauma Rehabilitation

Volumn 19, Issue 2, 2004, Pages 101-108

  Meythaler, Jay M ^a,b   Clayton, Warren ^a   Davis, Linda K ^a   Guin Renfroe, Sharon ^a   Brunner, Robert C ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Anoxia; Baclofen; Brain injury; Encephalopathy; Gamma amino butyric acid (GABA); Spasticity; Stroke

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; BACLOFEN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN INJURY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MICTURITION DISORDER; MORALITY; MUSCLE TONE; SCORING SYSTEM; SOMNOLENCE; SPASTICITY; STROKE; TENDON REFLEX; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; WILCOXON SIGNED RANKS TEST;

EID: 1842486037     PISSN: 08859701     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001199-200403000-00003     Document Type: Article

References (32)

1. Meythaler JM. Pharmacology update: intrathecal baclofen for spastic hypertonia in brain injury. J Head Trauma Rehabil. 1997;12:87-90.
2. Meythaler JM, Renfroe SG, Grabb PA, Hadley MN. Long-term continuously infused intrathecal baclofen for spastic/dystonic hypertonia in traumatic brain injury: 1-year experience. Arch Phys Med Rehabil. 1999;80:13-19.
3. Meythaler JM, Guin-Renfroe S, Brunner RC, Johnson A, Hadley MN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke. 2001;32:2099-2109.
4. Meythaler JM, McCary A, Hadley MN. Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. J Neurosurg. 1997;87:415-419.
5. Francisco GE, Kothari S, Huls C. GABA agonists and gabapentin for spastic hypertonia. N Am Clinics of Phys Med Rehabil. 2001;12:875-888.
6. Young RR, Delwaide PJ. Spasticity (part one of two parts). N Eng J Med. 1981;304:28-33.
7. Sandy KR, Gillman MH. Baclofen-induced memory impairment. Clin Neuropharm. 1985;8:294-295.
8. Hattab JR. Review of European clinical trials with baclofen. In: Feldman RG, Young RR, Kiella WP, eds. Spasticity Disordered Motor Control. Chicago: Year Book Medical Publishers; 1980:71-75.
9. Roy CW, Wakefield IR. Baclofen pseudopsychosis: case report. Paraplegia. 1986;24:318-321.
10. Mann NH. Functional management of spasticity after head injury. J Neuro Rehab. 1991;5:51-54.
11. Meythaler JM. Appendix. N Am Clinics of Phys Med Rehabil. 2001;12:953-956.
12. Meythaler JM. Use of intrathecally delivered medications for spasticity and dystonia in acquired brain injury. In: Yaksh, ed. Spinal Drug Delivery. New York: Elsevier; 1999;513-554.
13. Meythaler JM, Guin-Renfroe S, Johnson A, Brunner RC. Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch Phys Med Rehabil. 2001;82:1155-1163.
14. Gelber DA, Good DC, Dromerick A, Serrgay S, Richardson M. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke. 2001;32:1841-1846.
15. Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. Neurology 1994;44(suppl 9):S34-S43.
16. Cutter NC, Scott DD, Johnson JV, Whiteneck G. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil. 2000;81:164-169.
17. Priebe MM, Sherwood AM, Graves DE, Mueller M, Olson WH. Effectiveness of gabapentin in controlling spasticity: a quantitative study. Spinal Cord. 1997;35:171-175.
18. Mueller ME, Gruenthal M, Olson WL, Olson WH. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil. 1997;78:521-524.
19. Gracies JM, Nance P, Elovic E, et al. Traditional pharmacological treatments for spasticity. Part II. General and regional treatments. Muscle Nerve. 1997;(suppl 6):S92-S120.
20. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner. 1964;192:540-542.
21. Rudick RA, Breton D, Krall RL. The GABA-agonist progabide for spasticity in multiple sclerosis. Arch Neurol. 1987;44:1033-1036.
22. Young RR, Delwaide PJ. Spasticity (part two of two parts). N Eng J Med. 1981;304:96-99.
23. Ashby P, Verrier M, Lightfoot E. Segmental reflex pathways in spinal shock and spinal spasticity in man. J Neurol Neurosurg Psychiatry. 1974;37:1352-1360.
24. Meythaler JM, DeVivo MJ, Hadley M. Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Arch Phys Med Rehabil. 1996;77:461-466.
25. Albright LA, Barron WB, Fasick MP, Polinko P, Janosky J. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. J Am Med Assoc. 1993;270:2475-2477.
26. Nance PW. Alpha adrenergic and serotonergic agents in the treatment of spastic hypertonia. N Am Clinics of Phys Med Rehabil. 2001;12:889-905.
27. Ford B, Green P, Louis ED, et al. Use of intrathecal baclofen in the treatment of patients with dystonia. Arch Neurol. 1996;53:1241-1246.
28. Coffey RJ, Cahill D, Steers W, et al. (The Intrathecal Baclofen Multicenter Study Group). Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg. 1993;78:226-232.
29. Grabb PA, Guin-Renfroe S, Meythaler JM. Midthoracic catheter tip placement for intrathecal baclofen administration in children with quadriparetic spasticity. Neurosurgery. 1999;45:833-837.
30. Meythaler JM, Roper JF, Davis L, Brunner RC. Cyproheptadine in intrathecal baclofen withdrawal: a case series. Arch Phys Med Rehabil. 2003;84:638-642.
31. Nance PW, Bugaresti J, Shellenberger K, Sheremata W, Martinez-Arziala A. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. Neurology. 1994;44(suppl 9):S44-S52.
32. Elovic E. Principles of pharmaceutical management of spastic hypertonia. N Am Clinics of Phys Med Rehabil. 2001;12:793-816.